X4 Pharmaceuticals Inc SEC Filings

X4 Pharmaceuticals is undertaking a major restructuring to focus resources on completing its 4WARD Phase 3 trial in chronic neutropenia. The plan includes reducing its workforce by approximately 50%, which is expected to generate about $13 million in annualized cost savings and result in an estimated $3.3 million of severance and related cash charges.

As part of the actions, the company terminated its Chief Operating Officer, Chief Commercial Officer, and Chief Legal & Compliance Officer effective September 15, 2025, and its Chief Medical Officer resigned effective September 16, 2025. The Board appointed John Volpone as Chief Operating Officer, and he will also continue serving as President. X4 notes that actual restructuring costs and benefits may differ from current estimates.

X4 Pharmaceuticals, Inc. filed a shelf registration on Form S-3 to register resale of shares held by selling stockholders and to cover various resale methods. The company notes its common stock trades on Nasdaq under XFOR and reported a last sale price of $3.39 on September 8, 2025. X4 highlights the April 29, 2024 FDA approval of mavorixafor marketed as XOLREMDI for patients 12+ with WHIM syndrome and sale of its pediatric review voucher. The filing discloses a 1-for-30 reverse stock split effective April 28, 2025 and contains PwCs audit report with an explanatory paragraph regarding the companys ability to continue as a going concern. The prospectus describes extensive pre-funded warrants and beneficial ownership limitations held by institutional investors and standard indemnification and resale mechanics for Selling Stockholders.

X4 Pharmaceuticals, Inc. has filed a new Form S-8 registration statement to increase the number of shares available under its Amended and Restated 2019 Inducement Equity Incentive Plan. This filing uses a streamlined process that incorporates by reference several prior S-8 registration statements covering the same plan and other employee benefit plans.

The company lists its key governing documents, the equity plan itself, and related legal opinions and consents as exhibits. The registration statement is signed on behalf of X4 Pharmaceuticals by Executive Chairman Adam R. Craig and other senior officers and directors, who also grant powers of attorney to authorize future amendments to this S-8.

X4 Pharmaceuticals, Inc. filed a Form D reporting a Regulation D, Rule 506(b) exempt offering that raised $84,999,985, with the entire amount marked as sold and $0 remaining. The filing indicates the first sale date as 2025-08-13 and the issuer lists its principal place of business in Boston, Massachusetts. The offering included equity and options/warrants (and the securities to be acquired upon exercise) and reports 18 investors to date. Sales commissions are disclosed as $3,300,000 (estimated). The Form D was signed by Chief Legal Officer Natasha Thoren on behalf of the issuer.

X4 Pharmaceuticals, Inc. reported that on August 22, 2025, directors David McGirr and R. Keith Woods resigned from its board of directors, including all board committees, effective immediately. The company stated that their resignations were not due to any disagreement regarding operations, policies, or practices.

Following these departures, Michael Wyzga was appointed chair of the board’s audit committee, and Francoise de Craecker and Gary Bridger were appointed as members of the audit committee, ensuring the committee remains staffed to oversee the company’s financial reporting and controls.

Biotechnology Value Fund and affiliated entities disclosed beneficial ownership stakes in X4 Pharmaceuticals (XFOR). Collectively certain Reporting Persons hold 2,243,659 shares, representing approximately 9.9% of the outstanding common stock on the filing date. Individually, BVF holds 1,168,649 shares (~5.2%), BVF2 holds 906,855 shares (~4.0%), and Biotechnology Value Trading Fund OS holds 123,369 shares (less than 1%). The reporting group also holds pre-funded warrants exercisable for an aggregate of 1,288,288 shares at $0.001 per share, subject to a blocker that limits current exercisable warrants to 9,917 shares for the Reporting Persons as of August 20, 2025. The filing clarifies shared voting and dispositive powers among fund entities, GP entities, Partners, BVF Inc. and Mark N. Lampert and includes a joint filing agreement as Exhibit 99.1.

Deep Track entities and David Kroin report beneficial ownership of 2,366,995 shares of X4 Pharmaceuticals (XFOR), representing 9.99% of the class. The filing shows shared voting and dispositive power over those shares and states the position was not acquired to change control. The beneficial-ownership calculation references the issuer's reported share counts and convertible instruments and notes the inclusion of 4,162,137 pre-funded warrants exercisable subject to a 9.99% maximum-percentage exercise limitation that prevents exercise if it would push ownership above 9.99%. The filing is a joint Schedule 13G by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin and includes signatures dated August 19, 2025.

Trails Edge reports a 9.9% passive stake in X4 Pharmaceuticals. The filing shows Trails Edge Biotechnology Master Fund, LP directly holds 1,571,478 common shares and 745,675 shares underlying prefunded warrants, totaling 2,317,153 shares, which represent 9.9% of the outstanding common stock as of the Event Date. Trails Edge Capital Partners, LP (investment manager) and Ortav Yehudai (CIO) each may be deemed to beneficially own the same amount because of managerial and voting discretion. The filing discloses an issuance limitation that excludes 1,910,069 warrant shares from beneficial ownership calculations to avoid exceeding 9.99%.

Coastlands Capital and affiliated persons report acquiring a 9.99% beneficial ownership stake in X4 Pharmaceuticals (XFOR) following an August 2025 financing. The Reporting Persons hold an aggregate position equal to 2,479,645 shares of Common Stock on a fully‑diluted basis subject to a beneficial ownership blocker. Coastlands purchased a pre‑funded warrant exercisable for up to 7,047,216 shares for $9,999,999.50 and directly holds 107,500 shares purchased on August 12, 2025 for $1.7074 per share. The August 2025 Financing issued 11,040,776 shares and pre‑funded warrants to investors at $1.42 per share and $1.419 per pre‑funded warrant, respectively, and closed August 13, 2025. The Reporting Persons used working capital to fund their purchase, have registration rights for resale, and note Board changes at the Company including termination of the CEO and CFO and appointments of an Executive Chairman, new CFO and new President.